TDC
TVRD

Thompson Davis & Co’s Tvardi Therapeutics TVRD Stock Holding History

Thompson Davis & Co’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$22K Buy
25
+22
+733% +$15.9K 0.05% 311
2018
Q2 		$2K Buy
+3
New +$1.52K ﹤0.01% 627

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Thompson Davis & Co's TVRD Position: Q3 2018 in Review

Thompson Davis & Co increased its Tvardi Therapeutics (TVRD) stake by 733% in Q3 2018, buying an estimated $15.9K and bringing the position to 25 shares worth $22K. The position accounts for 0.05% of the portfolio, ranked #311.

Thompson Davis & Co first reported a position in TVRD in Q2 2018 and has held it in 2 quarters since. 146 funds tracked by Wall St. Rank hold TVRD as of Q3 2018.

  • Thompson Davis & Co held 25 shares of Tvardi Therapeutics worth $22K as of Q3 2018.
  • Thompson Davis & Co bought 22 Tvardi Therapeutics shares in Q3 2018, an estimated $15.9K.
  • Tvardi Therapeutics made up 0.05% of Thompson Davis & Co's portfolio in Q3 2018, its #311 holding.
  • Thompson Davis & Co first reported a position in Tvardi Therapeutics in Q2 2018 and has held it in 2 quarters since.
  • 146 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.